Mary Heenan

546 citations
11 papers · 464 indexed · h-index 9
Topics
Drug Transport and Resistance Mechanisms (6 papers)Pharmacogenetics and Drug Metabolism (3 papers)Cancer therapeutics and mechanisms (2 papers)

In The Last Decade

Mary Heenan

11 papers receiving 445 citations

Peers

Mary Heenan
Comparison fields: 5 of 82
  • Oncology 222
  • Molecular Biology 212
  • Pharmacology 79
  • Organic Chemistry 59
  • Pulmonary and Respiratory Medicine 42
Replace Paulo Eduardo Pizão with:
Paulo Eduardo Pizão Netherlands
Hsiou‐Ting Kuo Canada
Wolfgang Schwede Germany
Harold Mastalerz United States
Douglas D. Leipold United States
Xiaoying Lan China
Athanasios Papageorgiou Greece
Heather M. Brechbuhl United States
Smita Matkar United States
Gérard Bastian France
Mary Heenan relative to Paulo Eduardo Pizão Netherlands Paulo Eduardo Pizão's profile →
Citations per field
00.5×3.2×
Paulo Eduardo Pizão · 1×
Citations per year

Countries citing papers authored by Mary Heenan

Since Specialization
Citations

This map shows the geographic impact of Mary Heenan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Heenan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Heenan more than expected).

Fields of papers citing papers by Mary Heenan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Heenan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Heenan. The network helps show where Mary Heenan may publish in the future.

Co-authorship network of co-authors of Mary Heenan

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Heenan. A scholar is included among the top collaborators of Mary Heenan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Heenan. Mary Heenan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
#WorkIndexed citations
1 32
2
Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines.
41
3 37
4
Construction and transfection of a ribozyme targeting human caspase-3.
4
5
Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer.
27
6 28
7 34
8 220
9 28
10 8
11 5

About Mary Heenan

Mary Heenan is a scholar working on Pharmacology, Oncology and Pharmacology, having authored 11 papers that have together received 464 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (6 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Cancer therapeutics and mechanisms (2 papers). The work is most often cited by research in Oncology (222 citations), Pharmacology (79 citations) and Toxicology (11 citations). Mary Heenan has collaborated with scholars based in Ireland, United Kingdom and United States. Frequent co-authors include Martin Clynes, Robert O’Connor, Shirley Coyle, Kevin Kavanagh, Steven Verhaegen, Róisı́n NicAmhlaoibh, Lisa Connolly, Verena Murphy, Laura Breen and Lorraine O’Driscoll. Their work appears in journals such as British Journal of Cancer, International Journal of Cancer and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026